risk assessment after relapse of cml
Published 6 years ago • 126 plays • Length 3:27Download video MP4
Download video MP3
Similar videos
-
4:18
diagnosis of relapsed cml and risk status
-
2:03
nilotinib benefits relapsed patients with cml after treatment discontinuation
-
3:47
relapsed cml: mutation testing and therapy choices
-
4:44
the deciding factors for cml treatment
-
3:45
treatment approach for relapsed cml
-
30:14
when can tkis be stopped in cml?
-
4:12
rationale for tki therapy in relapsed cml
-
9:21
relapse after cml treatment discontinuation
-
3:46
cml: rationale for mutation testing and tki therapy
-
2:25
dose reduction and third-line therapy for cml
-
3:54
managing tki therapy in cml
-
7:39
frontline treatment for cml with bcr-abl-targeted tkis
-
1:06:19
the sequel to the targeted therapy era in cml
-
7:32
cml as an ideal cancer for targeted therapy with tki
-
1:39:04
genomic based risk assessment in cml
-
6:51
resistance to targeted-tki treatment in patients with cml
-
58:32
myeloid leukemias: a model for molecular diagnostics and targeted cancer therapy - jerald radich, md
-
4:06
challenges in management of chronic phase cml
-
21:14
cml molecular monitoring: practical advice